Related Experiment Video
Updated: Sep 18, 2025

NF-κB-dependent Luciferase Activation and Quantification of Gene Expression in Salmonella Infected Tissue Culture Cells
Published on: January 12, 2020
NF-κB in inflammation and cancer
Hongmei Mao1, Xiaocui Zhao1, Shao-Cong Sun2,3
1Institute for Immunology, Chinese Institutes for Medical Research, Beijing, China.
None:
Nuclear factor-κB (NF-κB) is a family of transcription factors that transactivates genes associated with a wide range of biological processes, including immune responses, inflammation, cell growth and survival. Dysregulated NF-κB activation contributes to acute and chronic inflammatory disorders, mostly through the aberrant induction of genes encoding proinflammatory factors and metabolic disorders. Abnormal NF-κB activation also influences the development and stability of regulatory T cells, contributing to the pathogenesis of autoimmune disorders. Given the critical role of inflammation in promoting oncogenesis, the proinflammatory role of NF-κB is also linked to cancer development. In addition, aberrant NF-κB activation contributes to uncontrolled tumor cell proliferation, survival, metabolism, metastasis, tumor angiogenesis and therapy resistance. These pathological functions of NF-κB highlight its potential as a therapeutic target for both inflammatory diseases and cancer. In this review, we summarize recent findings regarding the role of NF-κB in these pathological processes and discuss the underlying mechanisms. We also explore potential therapeutic strategies aimed at targeting the NF-κB pathway for disease treatment, along with an analysis of possible challenges.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Co-activators and Co-repressors
The Intrinsic Apoptotic Pathway
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
The JAK-STAT Signaling Pathway
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

